This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Archer Daniels Midland(ADM) downgraded at BofA/Merrill from Buy to Underperform, Bank of America/Merrill Lynchs said. Favorable grains positions could reverse. $32 price target.
American Eagle(AEO - Get Report) downgraded at Janney from Buy to Neutral, Janney Montgomery said. $15 price target. Channel checks continue to show weaker demand.
Alkermes(ALKS) upgraded at Leerink to Outperform, Leerink Swann said. ELN purchase should help augment organic growth potential.
Sotheby's(BID - Get Report) downgraded at Craig-Hallum from Buy to Accumulate, Craig-Hallum said. Company is facing increased competition. $50 price target.
Calpine(CPN - Get Report) upgraded at Dahlman Rose from Hold to Buy. $20 price target. Company has attractive exposure to California and Texas.
Cisco Systems(CSCO - Get Report) rated new Buy at BGC Partners. $24 price target. Company has a solid balance sheet and is leveraged to growth in mobile video demand.
Diodes(DIOD) downgraded at BMO to Market Perform, BMO Capital Markets said. Valuation call, based on a $34 price target.
FirstEnergy(FE) price target raised at Citi to $41 from $36. Story improving but valuation reflects catalysts, Citigroup said. Maintain Hold rating.
FirstEnergy(FE) upgraded at Wells from Market Perform to Outperform, Wells Fargo said. Estimates also boosted, given better power market trends.
Gamco Investors(GBL) upgraded at BofA/Merrill from Neutral to Buy, Bank of America/Merrill Lynch said. $61 price target. Company is realizing higher organic growth.
GenOn Energy(GEN) downgraded at Dahlman Rose from Buy to Hold. Valuation call.
Jones Apparel(JNY) downgraded at Goldman from Neutral to Sell, Goldman Sachs said. $11 price target. Estimates also cut, as the company is facing lower end-market demand.
Medivation(MDVN) initiated at Citi with a Buy rating and $35 price target. Biopharma with two promising phase 3 trials, Citigroup said.
Mindray Medical(MR) upgraded at Oppenheimer from Perform to Outperform. $32 price target. Company is seeing better operating momentum, with China driving overseas growth.
Ralcorp(RAH) downgraded at William Blair from Outperform to Market Perform, William Blair said. Expect little upside potential from the CAG bid.